SCHEMBL5729494

SCHEMBL5729494

CCc1nc(C2CCCC2)n2nc(-c3cc(C)cc(C)n3)[nH]c(=O)c12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 8/20 0.50
PDE1A P54750 6/20 0.48
PDE1B Q01064 6/20 0.48
PDE1C Q14123 6/20 0.48
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KHK P50053 1/20 0.32
ADORA2A P29274 2/20 0.31
ADORA2B P29275 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CCNE2 O96020 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5884082 0.83 PDE5A (0.52) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5731191 0.82 PDE5A (0.47) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5884434 0.81 PDE5A (0.49) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5730383 0.80 PDE5A (0.54) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5731208 0.80 PDE5A (0.49) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5884355 0.80 PDE5A (0.55) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5730895 0.79 PDE5A (0.50) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5884416 0.79 PDE5A (0.54) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5883869 0.79 PDE5A (0.54) PDE5APDE1APDE1BPDE1CKMT2A
SCHEMBL5731166 0.78 PDE5A (0.47) PDE5APDE1APDE1BPDE1CKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060293326-A1 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases BAYER HEALTHCARE AG (DE) 2006-12-28 US disclosed
EP-1399439-B1 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES BAYER HEALTHCARE AG (DE) 2006-06-14 EP disclosed
EP-1399439-A1 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES Bayer HealthCare AG (DE) 2004-03-24 EP disclosed
WO-2002098873-A1 2-HETEROARYL-IMIDAZOTRIAZINONES AND THEIR USE IN THE TREATMENT OF INFLAMMATORY OR IMMUNE DISEASES BAYER HEALTHCARE AG (DE) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293326-A1 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases REL, AHR, SULT2A1 PDE5A 3518/4885PDE1A 4223/4885PDE1B 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.